NIH Considers Exclusive License for HIV and HCV Vaccine Inventions

Summary

The National Institutes of Health (NIH) is considering granting a limited, worldwide exclusive license to use certain HIV and HCV vaccine inventions, originally developed by AriaVax, Inc. The license would be for inventions related to peptomers with enhanced immunogenicity and synthetic peptides, as described in U.S. patents 5,750,332 and 5,066,716.